In addition, blocking of IL-23 by IL-12/23p40 or IL-23p19 blocker results in highly effective clinical outcomes compared to conventional immunosuppressive agents, further implicating that lesional IL-23 production from inflammatory DCs is a key molecular event in the psoriasis pathogenesis [83]. The gene discussed is IL23A; the disease is psoriasis.